Product Name :
Miglustat Hydrochloride
Description:
Miglustat, also known as OGT 918 and NB-DNJ, is a drug developed by Actelion and is used primarily to treat Type I Gaucher disease (GD1). Miglustat inhibits glucosylceramide synthase, an essential enzyme for the synthesis of most glycosphingolipids (it forms glucosylceramide and accumulates within the macrophages). Miglustat is used to treat adults with mild-to-moderate Type I Gaucher disease and it is the first treatment to be approved for patients with Niemann–Pick type C disease
CAS:
210110-90-0
Molecular Weight:
255.74
Formula:
C10H22ClNO4
Chemical Name:
(2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol hydrochloride
Smiles :
Cl.CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO
InChiKey:
QPAFAUYWVZMWPR-ZSOUGHPYSA-N
InChi :
InChI=1S/C10H21NO4.ClH/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12;/h7-10,12-15H,2-6H2,1H3;1H/t7-,8+,9-,10-;/m1./s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Miglustat, also known as OGT 918 and NB-DNJ, is a drug developed by Actelion and is used primarily to treat Type I Gaucher disease (GD1). Miglustat inhibits glucosylceramide synthase, an essential enzyme for the synthesis of most glycosphingolipids (it forms glucosylceramide and accumulates within the macrophages). Miglustat is used to treat adults with mild-to-moderate Type I Gaucher disease and it is the first treatment to be approved for patients with Niemann–Pick type C disease|Product information|CAS Number: 210110-90-0|Molecular Weight: 255.Sulfasalazine Protocol 74|Formula: C10H22ClNO4|Synonym:|N-Butyldeoxynojirimycin, Hydrochloride|NB-DNJ hydrochloride|OGT918 hydrochloride|Zavesca hydrochloride|Chemical Name: (2R,3R,4R,5S)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol hydrochloride|Smiles: Cl.Odevixibat Purity CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO|InChiKey: QPAFAUYWVZMWPR-ZSOUGHPYSA-N|InChi: InChI=1S/C10H21NO4.PMID:32962420 ClH/c1-2-3-4-11-5-8(13)10(15)9(14)7(11)6-12;/h7-10,12-15H,2-6H2,1H3;1H/t7-,8+,9-,10-;/m1./s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|Products are for research use only. Not for human use.|
